What is claimed is:

1. A compound of Formula I:



Formula I

wherein:

R^1 is C_{1-6}alkyl;

R^2 is C_{5-14}aryl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{2-9}heterocycle, or C_{2-9}heteroaryl, wherein each R^2 group is optionally substituted by one to four substituents selected from halo, C_{1-6}alkyl, C_{1-6}hetereoalkyl, or C_{1-6}alkylene or C_{1-6}hetereoalklylene wherein said C_{1-6}alkylene or C_{1-6}hetereoalklylene are bonded to adjacent carbon atoms on said C_{5-14}aryl, C_{3-7}cycloalkyl, C_{3-7}cycloalkenyl, C_{3-9}heterocycle, or C_{5-9}heteroaryl to form a fused ring;

L is a bond, -C_{1-3}alkylene-, -SO_2-, -C(O)-, -C(S)-, -C(NH)-, -C(O)NH-, -C(O)$NHCH_2$-, -C(O)OCH_2-, -C(O)O-, -C(O)C(O)-, -SO_2-NH- , or –CH_2C(O)-;

R^3 is H, CN, C_{1-6}alkyl, C_{5-14}aryl, CH_2C_{5-14}aryl, CH_2C_{3-7}cycloalkyl, C_{3-7}cycloalkyl, C_{3-7}spirocycloalkyl, C_{3-7}cycloalkenyl, C_{2-9}heterocycle, or C_{2-9}heteroaryl, wherein each R^3 group is optionally substituted by one to four substituents selected from halo, C_{1-6}alkyl, C_{2-8}bridgedheterocycle, C_{3-7}cycloalkyl, C_{1-3}fluoroalkyl, -OC_{1-6}alkyl, -C(O)R^4, -C(O)NR^4, -C(O)NHR^4, C_{5-14}aryl, C_{1-6}hetereoalkyl, -$B(OH)_2$, C_{2-9}heterocycle, C_{1-6}heteroaryl, -C(O)OC_{1-6}alkyl, or two substituents bonded to adjacent atoms may bond together to form a fused ring and that fused ring may optionally be substituted with R^4;

R^4 is CN, halo, -OC_{1-6}alkyl, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{2-9}heterocycle, or C_{5-14}aryl;

and wherein each heterocycle, heteroaryl, heteroalkyl, and heteroalkylene comprises one to three heteroatoms selected from S, N, B, or O.

2. A compound according to Claim 1 wherein R^1 is C_{1-6}alkyl.

3. A compound according to Claim 2 wherein R^1 is t-butyl.



10. A compound according to Claim 1 wherein the compound is



11. A pharmaceutically acceptable salt of a compound according to any of Claims 1-10.

12. A pharmaceutical composition comprising a compound or salt according to any of Claims 1-11.

13. Use of a composition according to Claim 12 in the manufacture of a medicament for treating a viral infection in a patient mediated at least in part by a virus in the *retrovirus* family of viruses wherein said viral infection is mediated by HIV virus.

14. A compound or salt as defined in any of Claims 1-11 for use in medical therapy.

15. A compound or salt as defined in any of Claims 1-11 for use in the treatment of a viral infection in a human mediated by HIV virus.

16. The use of a compound or salt as defined in any of Claims 1-11 in the manufacture of a medicament for use in the treatment of a viral infection in a human mediated by HIV virus.